![]() |
|
|
Vol. 61, Issue 5, 1211-1221, May 2002
Molecular Pharmacology Group, Division of Biochemistry and
Molecular Biology, Institute of Biomedical and Life Sciences,
University of Glasgow, Glasgow, Scotland, United Kingdom (P.J.W., E.K.,
G.M.); and Molecular Pharmacology and Biochemistry, Department of
Enabling Science and Technology, Astra-Zeneca, Alderley Park,
Macclesfield, Cheshire, England, United Kingdom (G.W.)
Fusion proteins between the human 5-hydroxytryptamine
(5-HT)1A receptor and either wild type or certain pertussis
toxin-resistant forms of Go1
and Gi1
display constitutive GTPase activity that can be inhibited by the
inverse agonist spiperone. Addition of recombinant regulator of G
protein signaling (RGS) 1 or RGS16 to membranes expressing these fusion
proteins resulted in elevation of this constitutive GTPase activity
without significantly altering the binding affinity of
antagonist/inverse agonist ligands. For a 5-HT1A
receptor-(Cys351Ile)Go1
fusion protein the
increase in basal GTPase activity was greater than 4-fold. Enzyme
kinetic analysis demonstrated that the effect of RGS1 was as a
GTPase-activating protein for the fusion construct. In the presence of
the RGS proteins, both agonists and inverse agonists produced much more
robust regulation of high-affinity GTPase activity than in their
absence. This allowed detection of the partial agonist nature of
WAY100635, which has been described previously as a neutral antagonist
at the 5-HT1A receptor. Of a range of ligands studied, only
haloperidol functioned as a neutral ligand in the presence of RGS1.
These studies show that addition of a recombinant RGS protein provides
a simple and novel means to elevate the fraction of basal membrane
GTPase activity contributed by the constitutive activity of a receptor.
By so doing, it also greatly enhances the ability to detect and analyze the effects of inverse agonists and to discriminate between neutral ligands and those with low levels of positive intrinsic efficacy.
This article has been cited by other articles:
![]() |
M. J. Clark, J. J. Linderman, and J. R. Traynor Endogenous Regulators of G Protein Signaling Differentially Modulate Full and Partial {micro}-Opioid Agonists at Adenylyl Cyclase as Predicted by a Collision Coupling Model Mol. Pharmacol., May 1, 2008; 73(5): 1538 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Milligan Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective Mol. Pharmacol., December 1, 2003; 64(6): 1271 - 1276. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Osterhout, A. A. Waheed, A. Hiol, R. J. Ward, P. C. Davey, L. Nini, J. Wang, G. Milligan, T. L. Z. Jones, and K. M. Druey Palmitoylation Regulates Regulator of G-protein Signaling (RGS) 16 Function: II. PALMITOYLATION OF A CYSTEINE RESIDUE IN THE RGS BOX IS CRITICAL FOR RGS16 GTPase ACCELERATING ACTIVITY AND REGULATION OF Gi-COUPLED SIGNALING J. Biol. Chem., May 23, 2003; 278(21): 19309 - 19316. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Newman-Tancredi, D. Cussac, L. Marini, and M. J. Millan Antibody Capture Assay Reveals Bell-Shaped Concentration-Response Isotherms for h5-HT1A Receptor-Mediated Galpha i3 Activation: Conformational Selection by High-Efficacy Agonists, and Relationship to Trafficking of Receptor Signaling Mol. Pharmacol., September 1, 2002; 62(3): 590 - 601. [Abstract] [Full Text] [PDF] |
||||